Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Randomized clinical trial comparing concomitant and tailored therapy for eradication of Helicobacter pylori infection (CROSBI ID 296856)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Perković, Nikola ; Meštrović, Antonio ; Božić, Joško ; Pavičić Ivelja, Mirela ; Vuković, Jonatan ; Kardum, Goran ; Šundov, Željko ; Tonkić, Marija ; Puljiz, Željko ; Vukojević, Katarina et al. Randomized clinical trial comparing concomitant and tailored therapy for eradication of Helicobacter pylori infection // Journal of personalized medicine, 11 (2021), 6; 534, 10. doi: 10.3390/jpm11060534

Podaci o odgovornosti

Perković, Nikola ; Meštrović, Antonio ; Božić, Joško ; Pavičić Ivelja, Mirela ; Vuković, Jonatan ; Kardum, Goran ; Šundov, Željko ; Tonkić, Marija ; Puljiz, Željko ; Vukojević, Katarina ; Tonkić, Ante

engleski

Randomized clinical trial comparing concomitant and tailored therapy for eradication of Helicobacter pylori infection

As high clarithromycin resistance (>20%) in the Split-Dalmatia region of Croatia hinders the treatment of H. pylori infection, the primary objective of this study was to compare concomitant quadruple with the tailored, personalized therapy as first-line eradication treatment of H. pylori. In an open-label, randomized clinical trial, 80 patients with H. pylori infection were randomly assigned to either concomitant (esomeprazole 40 mg, amoxicillin 1 gr, metronidazole 500 mg, clarithromycin 500 mg, twice daily for 14 days) or tailored therapy in accordance with the results of the antimicrobial susceptibility testing. Eradication status was assessed 4 weeks after treatment. Eradication rates were significantly higher in tailored group than in concomitant group both in intention-to- treat (70 vs. 92.5%, p = 0.010) and per-protocol (87.5 vs. 100%, p = 0.030) analysis in the setting of increasing antibiotic resistance (clarithromycin 37.5%, metronidazole 17.5%, dual resistance 10%). Adverse effects were more frequent in the concomitant group (32.5 vs. 7.5%, p = 0.006). Tailored therapy achieves higher eradication with a lower adverse events rate. With the increasing resistance of H. pylori strains to antibiotic treatment, eradication regimes with such characteristics should be strongly considered as a reasonable choice for first- line treatment.

H. pylori ; concomitant therapy ; tailored therapy ; gastritis ; antimicrobial resistance

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

11 (6)

2021.

534

10

objavljeno

2075-4426

10.3390/jpm11060534

Povezanost rada

Kliničke medicinske znanosti

Poveznice
Indeksiranost